Quotables
"To place a man in a multi-stage rocket and project him into the controlling gravitational field of the moon where the passengers can make scientific observations, perhaps land alive, and then return to earth--all that constitutes a wild dream worthy of Jules Verne. I am bold enough to say that such a man-made voyage will never occur regardless of all future advances."
Lee deForest, American radio pioneer ; 1957
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188111 | Amide and carbamate derivatives of alkyl substituted -[4-(4-amino-1-imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods Amide and carbamate derivatives of N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides with an ethyl, methyl, or n-propyl substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, and m... | 05/29/2012 |
| 8143269 | Inhibitors of store operated calcium release Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with othe... | 03/27/2012 |
| 8110583 | Tetrahydroquinoline derivatives Compounds of the formula I, in which s, k, I, W, R1, R2, R3, and U have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours. ... | 02/07/2012 |
| 8080560 | Immune response modifier formulations containing oleic acid and methods Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 12/20/2011 |
| RE42802 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use Compounds of the general formula I wherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic whe... | 10/04/2011 |
| 8017624 | Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV en... | 09/13/2011 |
| 8008317 | Inhibitors of akt activtiy The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compo... | 08/30/2011 |
| 7928117 | Method of inducing cytokine biosynthesis Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 04/19/2011 |
| 7928116 | Method of treating actinic keratosis Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 04/19/2011 |
| 7928118 | Reduction of imiquimod impurities in pharmaceutical creams Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 04/19/2011 |
| 7919501 | Method of controlling formation of imiquimod impurities Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 04/05/2011 |
| 7915277 | Method of treating genital or peri-anal warts Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/29/2011 |
| 7915279 | Method of treating mollescum contagiosum Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/29/2011 |
| 7915278 | Method of treating basal cell carcinoma Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/29/2011 |
| 7906527 | Reduction of imiquimod impurities using refined oleic acid Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/15/2011 |
| 7906526 | Method of treating a dermal and/or mucosal associated condition Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/15/2011 |
| 7906524 | Pharmaceutical cream having similar or less levels of imiquimod impurity formation as cream with BHA (comparator) Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/15/2011 |
| 7906525 | Reduction of imiquimod impurities at four months using refined oleic acid Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/15/2011 |
| 7902209 | Method of preparing a pharmaceutical cream and minimizing imiquimod impurity formation Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902211 | Method of inducing interferon biosynthesis Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902208 | Treating allergic and inflammatory conditions A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering a... | 03/08/2011 |
| 7902210 | Reduction of IMIQUIMOD impurities at two months using refined oleic acid Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902214 | Method of treating a mucosal and/or dermal associated condition Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902215 | Pharmaceutical creams with reduced imiquimod impurities Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902213 | Pharmaceutical cream with reduced imiquimod impurities at four months using refined oleic acid Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902216 | Pharmaceutical creams with refined oleic acid Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7902212 | Reduction of imiquimod impurities at six months using refined oleic acid Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 03/08/2011 |
| 7893081 | Tyrosine kinase inhibitors This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide, an inhibitor of tyrosine kinases, in particular the receptor tyrosine kinase M... | 02/22/2011 |
| 7846939 | Salts and mixture of 9-oxoacridine-10-acetic acid with 1-alkylamino-1-desoxy-polyols, pharmaceutical compositions containing said agents and treatment methods The invention relates to salts of 1-alkylamino-1-deoxypolyols and 9-oxoacridine-10-acetic acid of the general formula (I): wherein A+ is (II) | 12/07/2010 |
| 7838531 | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis Although it can be farnesylated, the mutant lamin A protein expressed in Hutchison Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effect... | 11/23/2010 |
| 7816368 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics The present disclosure relates to pyridoindolone derivatives of general formula (I): in which R1 to R5 are as defined in the specification, to processes for preparing said derivatives, and to methods o... | 10/19/2010 |
| 7790739 | Tyrosine kinase inhibitors The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related ... | 09/07/2010 |
| 7718666 | Pyrido [2,1-a] isoquinoline derivatives The present invention relates to compounds of formula (I) wherein R1 is as defined in the description, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis ... | 05/18/2010 |
| 7713989 | Glucocorticoid receptor modulators The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions cont... | 05/11/2010 |
| 7696221 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFκB inhibitors This invention provides estrogen receptor modulators having the structure: wherein R1 to R7 are as defined in the specification; or a pharmaceutically acceptable salt thereof. ... | 04/13/2010 |
| 7655672 | Immune response modifier formulations containing oleic acid and methods Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides. ... | 02/02/2010 |
| 7618979 | Pyridopyrrolizine and pyridoindolizine derivatives Pyridopyrrolizine and pyridoindolizine derivatives are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma. ... | 11/17/2009 |
| 7585871 | Phenanthridine carbonyl phenols The present invention relates generally to phenanthridine carbonyl compositions such as substituted phenanthridine carbonyl phenols of Formula 1: wherein R1 to R15 are as defined in the specification, ... | 09/08/2009 |
| 7550478 | Tyrosine kinase inhibitors The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention a... | 06/23/2009 |
| 7544696 | Spermicidal and/or antifungal composition and methods of using the same Hexahydroindenopyridine compounds are provided which act as spermicides and/or fungicides, spermicidal and/or fungicidal compositions containing the same, and methods for killing motile sperm and/or fungi using the compounds and compositions. ... | 06/09/2009 |
